Collagen Corporation
This article was originally published in The Gray Sheet
Executive Summary
Invests $1.6 mil. in additional funds in Mountain View, California-based GenPharm International, which is developing transgenic animal technology for use in human health care products. Collagen invested an initial $2 mil. in the company in May 1993. At the same time it announced Collagen's additional stake, GenPharm said that its European subsidiary, Gene Pharming Europe B.V., has produced human collagen from transgenic mouse milk. According to GenPharm, the success in mouse milk was necessary to establish that collagen could be correctly produced at commercially meaningful levels in milk. GenPharm says it has raised close to $8 mil. in equity financing "in the last several months"